{"generic":"Vaccinia Immune Globulin, Human","drugs":["Vaccinia Immune Globulin, Human","Vaccinia Immune Globulin, Human"],"mono":{"0":{"id":"928381-s-0","title":"Generic Names","mono":"Vaccinia Immune Globulin, Human"},"1":{"id":"928381-s-1","title":"Dosing and Indications","sub":[{"id":"928381-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>geriatric patients:<\/b> safety and efficacy have not been established<\/li><li><b>Vaccinia, eg, in eyes (except isolated keratitis), mouth, or other areas of concern; eczema vaccinatum; progressive or severe generalized vaccinia; vaccinia infections in persons with skin disease, eg, burns, eczema, impetigo, varicella-zoster:<\/b> (Cangene manufacturer) 6,000 units\/kg IV; higher doses (9,000 units\/kg) may be considered if the patients fails to respond to the initial dose<\/li><li><b>Vaccinia, eg, in eyes (except isolated keratitis), mouth, or other areas of concern; eczema vaccinatum; progressive or severe generalized vaccinia; vaccinia infections in persons with skin disease, eg, burns, eczema, impetigo, varicella-zoster:<\/b> (DynPort manufacturer) 100 mg\/kg (2 mL\/kg) IV as an infusion at a rate of 1 mL\/kg\/hour for the first 30 minutes, increased to 2 mL\/kg\/hour for the next 30 minutes, then 3 mL\/kg\/hour for the remainder of the infusion, as tolerated; dose may be repeated depending on severity of symptoms and response to therapy; higher doses (200mg\/kg or 500 mg\/kg) may be considered if the patient fails to respond to the initial dose<\/li><\/ul>"},{"id":"928381-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy have not been established"},{"id":"928381-s-1-6","title":"Dose Adjustments","mono":"<b>renal impairment:<\/b> (DynPort manufacturer) use cautiously as vaccinia immune globulin is stabilized with 5% sucrose (2.5 grams sucrose per vial); use the lowest concentration available at the lowest rate feasible; higher doses (&gt; 400 mg\/kg) are not recommended"},{"id":"928381-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Vaccinia, eg, in eyes (except isolated keratitis), mouth, or other areas of concern; eczema vaccinatum; progressive or severe generalized vaccinia; vaccinia infections in persons with skin disease, eg, burns, eczema, impetigo, varicella-zoster<br\/>"}]},"2":{"id":"928381-s-2","title":"Black Box Warning","mono":"<b>Intravenous (Solution)<\/b><br\/>Immune globulin intravenous (human) (IGIV) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, proximal tubular nephropathy, and death. Use caution in patients predisposed to acute renal failure and administer at the minimum concentration available and the minimum rate of infusion practicable. Higher rates of renal failure were associated with IGIV products containing sucrose and administered at daily doses of 400 mg\/kg or greater. Vaccinia immune globulin contains sucrose (5%) as a stabilizer, and the recommended dose is 100 mg\/kg.<br\/>"},"3":{"id":"928381-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928381-s-3-9","title":"Contraindications","mono":"<ul><li>IgA deficiency (product contains trace amount of IgA); may develop antibodies to IgA with subsequent anaphylactic reactions<\/li><li>isolated vaccinia keratitis; possible corneal scarring<\/li><li>severe reaction to other immune globulin products<\/li><\/ul>"},{"id":"928381-s-3-10","title":"Precautions","mono":"<ul><li>diabetes mellitus; risk of renal dysfunction or acute renal failure<\/li><li>paraproteinemia; risk of renal dysfunction or acute renal failure<\/li><li>patients receiving nephrotoxic drugs; risk of renal dysfunction or acute renal failure<\/li><li>patients who are at least 65 years of age; risk of renal dysfunction or acute renal failure<\/li><li>pre-existing renal insufficiency; risk of renal dysfunction or acute renal failure<\/li><li>sepsis; risk of renal dysfunction or acute renal failure<\/li><li>volume depletion; risk of renal dysfunction or acute renal failure<\/li><li>blood glucose measurement in patients receiving vaccinia immune globulin should be done with a glucose-specific method to avoid interference by maltose; glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) based methods can cause falsely elevated glucose readings<\/li><li>human plasma derived product; possibility of transmission of blood-born infections<\/li><li>hypersensitivity reactions; administer in setting where appropriate equipment and trained personnel are available to manage acute anaphylaxis<\/li><li>patients at risk of thrombotic and thromboembolic events<\/li><\/ul>"},{"id":"928381-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"928381-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"928381-s-4","title":"Drug Interactions","sub":{"2":{"id":"928381-s-4-15","title":"Moderate","mono":"<ul><li>Bacillus of Calmette and Guerin Vaccine, Live (probable)<\/li><li>Influenza Virus Vaccine, Live (probable)<\/li><li>Measles Virus Vaccine, Live (probable)<\/li><li>Mumps Virus Vaccine, Live (probable)<\/li><li>Rotavirus Vaccine, Live (probable)<\/li><li>Rubella Virus Vaccine, Live (probable)<\/li><li>Smallpox Vaccine (probable)<\/li><li>Typhoid Vaccine, Live (probable)<\/li><li>Varicella Virus Vaccine (probable)<\/li><\/ul>"}}},"5":{"id":"928381-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction (0% to 12%), Urticaria (Mild to Moderate) (0% to 8%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (0% to 30%)<\/li><li><b>Musculoskeletal:<\/b>Backache (0% to 7%)<\/li><li><b>Neurologic:<\/b>Dizziness (0% to 21%), Headache (0% to 62%)<\/li><li><b>Other:<\/b>Diaphoresis (0% to 9.7%), Feels cold (0% to 20.7%), Feels hot (0% to 9.7%), Rigor (10% to 22.6%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Hemolytic anemia, Thrombosis<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Aseptic meningitis<\/li><li><b>Renal:<\/b>Acute renal failure, Hypokalemic nephropathy, Renal impairment, Renal tubular disorder, proximal<\/li><li><b>Respiratory:<\/b>Transfusion related acute lung injury<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},"6":{"id":"928381-s-6","title":"Drug Name Info","sub":{"0":{"id":"928381-s-6-17","title":"US Trade Names","mono":"Vaccinia Immune Globulin, Human<br\/>"},"2":{"id":"928381-s-6-19","title":"Class","mono":"Immune Serum<br\/>"},"3":{"id":"928381-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"8":{"id":"928381-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"928381-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 6630 L (solution)<\/li><li>Vd: 68.7 mL\/kg<\/li><\/ul>"},"4":{"id":"928381-s-8-27","title":"Elimination Half Life","mono":"<ul><li>30 days (solution)<\/li><li>21.6 days (lyophilized)<\/li><\/ul>"}}},"9":{"id":"928381-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>administer IV only<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>(Cangene manufacturer) may dilute with NS; do NOT dilute more than a 1 to 2 ratio; flush line with NS before use<\/li><li>(Cangene manufacturer) administer at a maximum rate of 2 mL\/min for patients 50 kg or greater; administer at a maximum rate of 0.04 mL\/kg\/min for patients &lt; 50 kg; the maximum assessed rate of infusion has been 4 mL\/min; decrease rate if adverse events develop<\/li><li>(Cangene manufacturer) begin infusion within 4 h of entering vial<\/li><li>(Dynport manufacturer) do not predilute<\/li><li>(Dynport manufacturer) do not shake, avoid foaming<\/li><li>(Dynport manufacturer) administer through a dedicated IV line using a 0.22 micron in-line filter and a constant infusion pump; may be piggybacked into a line containing NS, D5W, or D5NS; do NOT dilute more than a 1 to 2 ratio with any of these solutions<\/li><li>(Dynport manufacturer) infuse at rate of 1 mL\/kg\/h for 30 min, then 2 mL\/kg\/h for 30 min, then 3 mL\/kg\/h for remainder of infusion, as tolerated<\/li><li>(Dynport manufacturer) begin infusion within 6 h of entering the vial and complete within 12 h of entering the vial<\/li><\/ul><\/li><\/ul>"},"10":{"id":"928381-s-10","title":"Monitoring","mono":"<ul><li>clinical improvement, CBC<\/li><li>vital signs<\/li><li>signs and symptoms of intravascular hemolysis: consider hemolysis panel, urine dipstick, liver function, renal function, DIC screen<\/li><li>respiratory status<\/li><\/ul>"},"13":{"id":"928381-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause nausea, back pain, dizziness, headache, diaphoresis, cold or hot feeling, or rigor.<\/li><li>Advise patient to report signs\/symptoms of renal dysfunction, angioedema (deep swelling around eyes and lips and sometimes hands and feet), or thrombotic\/thromboembolic events.<\/li><li>Patient should report signs\/symptoms of aseptic meningitis (severe headache, nuchal rigidity, drowsiness, fever, photophobia, pain eye movement), especially between several hours to 2 days post-infusion.<\/li><li>Patient should report respiratory distress, especially 1 to 6 h post-infusion, as drug may cause transfusion-related acute lung injury.<\/li><li>Advise patient to avoid vaccines for up to 6 months following administration of vaccinia immune globulin.<\/li><\/ul>"}}}